DUBLIN - Endo International plc (NASDAQ: ENDP) announced that new post-hoc data from two Phase 3 studies of XIAFLEX (collagenase clostridium histolyticum, or CCH) in treating men with Peyronie's disease (PD) will be presented today in an oral presentation during the Sexual Medicine Society of North America (SMSNA) annual meeting.
'The data analysis discusses the importance of patient adherence when treating PD with XIAFLEX,' said Dr. Matthew J. Ziegelmann, urologist and the presenting author.
'Collagenase Clostridium Histolyticum Treatment for Peyronie's Disease: Analysis of Outcomes and Cumulative Benefits After Each Injection Cycle' was submitted by authors Matthew Ziegelmann, M.D.; Genzhou Liu, Ph.D.; Michael P. McLane, Ph.D.; Yiqun Hu, M.D., Ph.D.; and Landon Trost, M.D.
The SMSNA Annual Fall Scientific Meeting is taking place in Scottsdale, Arizona, October 21-24, 2021.
About the Data
A post-hoc analysis of pooled data from two randomized, double-blind, placebo-controlled studies Phase 3 trials was conducted to evaluate incremental changes in penile curvature over the course of CCH treatment in men with PD. The analysis included men who received at least one injection of study medication.1 XIAFLEX is an FDA-approved treatment for adult men with Peyronie's disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy.
Changes from baseline and from the previous penile curvature measurement were calculated after each of the four treatment cycles (weeks 6, 12, 18 and 24). CCH injections were administered in up to four treatment cycles at 6-week intervals; each cycle included two injections 1-3 days apart. For all patients, treatment included penile plaque modeling.1
Data support that incremental benefits were obtained from each of the four CCH treatment cycles administered to men with PD. Results may suggest incremental benefits with performing a full series of four CCH injections and penile modeling, even among men who were initially considered non-responders (achieved
(C) 2021 Electronic News Publishing, source ENP Newswire